Liège biotech Imcyse in liquidation after disappointing clinical results

Liège biotech Imcyse in liquidation after disappointing clinical results
Liège biotech Imcyse in liquidation after disappointing clinical results

The Liège biotechnology company Imcyse, specializing in immunotherapies, will be put into liquidation after disappointing clinical results, L’Echo reported on Thursday. The company plans to lay off all of its staff, around forty people.

Founded in 2010 as a spin-off from KU Leuven, Imcyse launched a phase 2 clinical study three years ago to evaluate the effectiveness of its treatment against type 1 diabetes.

The biotech also managed to raise 21.3 million euros three years ago, notably by welcoming Pfizer into its capital. A partnership had been concluded with the American pharmaceutical giant on rheumatoid arthritis.

However, the results of the phase 2 clinical study in type 1 diabetes, received in April, did not live up to expectations. As a result, Imcyse was unable to find the necessary funding to launch a possible new modified clinical trial.

This scenario is not isolated in the life sciences sector in Wallonia. Recently, the Cellaïon company also had to cease its activities after insufficient clinical results, while Mithra was carried away by a succession of management errors and disappointing sales.

Access to all features is reserved for healthcare professionals.

If you are a healthcare professional you must log in or register for free on our site to access all of our content.
If you are a journalist or if you wish to inform us, write to us at [email protected].

-

-

PREV Joe Biden tests positive for Covid, his candidacy under increasing pressure
NEXT US presidential election: Joe Biden tests positive for Covid-19 and cancels campaign speech: News